Full Press Release Details
Supernus to Present at September 2018 Wells Fargo Healthcare Conference
ROCKVILLE, Md., August 29, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company s management will present an overview and update of the Company s business, and host investor meetings, at the 2018 Wells Fargo Healthcare Conference.
Date: Wednesday, September 5, 2018
Place: The Westin Copley Place, Boston, Mass.
Investors interested in arranging a meeting with the Company s management during this conference should contact the conference coordinator.
A live webcast of the presentation can be accessed by visiting Events & Presentations in the Investor Relations section on the Company s website at www.supernus.com. An archived replay of these webcasts will be available for 60 days after the conference on the Company s website.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR (extended-release topiramate) for the prophylaxis of migraine headache and the treatment of epilepsy, and Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.